Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Eisai Co Ltd Announces Partnership With Newbridge to Market Breast Cancer Treatment Halaven (Eribulin) Across Middle East


Sunday, 17 Nov 2013 07:02pm EST 

Eisai Co Ltd announced that Halaven (eribulin) will be marketed in selected countries within the Middle East region through a new partnership between Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) and NewBridge Pharmaceuticals. Eribulin is indicated for the treatment of locally advanced or metastatic breast cancer, which has progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included two common types of chemotherapy, an anthracycline and a taxane, unless patients were not suitable for these treatments. 

Company Quote

4715.0
0.0 +0.00%
26 Dec 2014